Department of Dermatology, School of Medicine, Boston University, Boston, Massachusetts; Laser & Skin Surgery Center of New York, New York, New York.
Dermatol Surg. 2014 May;40(5):519-24. doi: 10.1111/dsu.12465. Epub 2014 Mar 7.
Many therapeutic options are available for treating keloids, but success rates vary widely, and the keloids often recur. The Food and Drug Administration has recently approved intralesional collagenase for the treatment of Dupuytren's contracture. This medication has not been explored for the treatment of earlobe keloids, a common problem.
To evaluate the safety and clinical efficacy of intralesional collagenase followed by compression for the treatment of earlobe keloids.
Six earlobe keloids in six patients were injected with a commercial collagenase preparation. Study participants were asked to use compression earrings daily thereafter. Patients were examined and photographed 1 day, 2 weeks, 4 weeks, 10 months, and 12 months after injection. Adverse events were assessed at each visit, and the keloids were measured and photographed.
All patients had a decrease in the size of their earlobe keloid by an average of 50% (p = .02). Three of the six participants chose to have their earlobe keloids surgically excised for cosmetic reasons 6, 8, and 11 months after enrollment, so measurements for data analysis for these patients were taken after only 1, 1 and 10 months. All participants returned for follow-up at the last study visit 1 year after study commencement. The three patients who completed the study were pleased with the improvement of their earlobe keloid, although complete clearance was not achieved. Side effects included injection site swelling, tenderness, and one ulceration that spontaneously resolved within 2 weeks.
Intralesional collagenase followed by compression appears to be a safe and modestly effective treatment for earlobe keloids. This approach warrants further investigation in larger studies with longer follow-up in motivated patients who decline surgical excision.
有许多治疗方法可用于治疗瘢痕疙瘩,但成功率差异很大,而且瘢痕疙瘩经常复发。食品和药物管理局最近批准了将胶原酶注射到病变部位治疗杜普伊特伦挛缩。这种药物尚未被探索用于治疗耳垂瘢痕疙瘩,这是一种常见的问题。
评估注射胶原酶联合压迫治疗耳垂瘢痕疙瘩的安全性和临床疗效。
6 名患者的 6 个耳垂瘢痕疙瘩注射了一种商业胶原酶制剂。此后,研究参与者被要求每天佩戴压迫耳环。在注射后 1 天、2 周、4 周、10 个月和 12 个月对患者进行检查和拍照。每次就诊时评估不良反应,并测量和拍照瘢痕疙瘩。
所有患者的耳垂瘢痕疙瘩大小平均减少了 50%(p=0.02)。6 名参与者中的 3 名出于美容原因选择在入组后 6、8 和 11 个月手术切除耳垂瘢痕疙瘩,因此这些患者的数据分析测量值仅在 1、1 和 10 个月后进行。所有参与者在研究开始后 1 年的最后一次研究访视时都返回进行随访。完成研究的 3 名患者对耳垂瘢痕疙瘩的改善感到满意,尽管没有完全清除。副作用包括注射部位肿胀、压痛和 1 处溃疡,溃疡在 2 周内自行愈合。
注射胶原酶联合压迫后似乎是治疗耳垂瘢痕疙瘩的一种安全且适度有效的方法。这种方法在拒绝手术切除的有动机患者中进行更大规模研究和更长时间随访时值得进一步研究。